OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company preparing to complete submissions for early market access in the U.S., U.K., Europe and AustraliaWHO recently accepted the proprietary brand name Herlystic™ for OST-HER2 (daznelimgene lisbac).Grasonville, Maryland--(Newsfile Corp. - October 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer...